Centessa Pharmaceuticals (CNTA) Enterprise Value (2022 - 2025)
Centessa Pharmaceuticals (CNTA) has disclosed Enterprise Value for 4 consecutive years, with -$246.2 million as the latest value for Q3 2025.
- On a quarterly basis, Enterprise Value rose 52.51% to -$246.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$246.2 million, a 52.51% increase, with the full-year FY2024 number at -$482.2 million, down 87.95% from a year prior.
- Enterprise Value was -$246.2 million for Q3 2025 at Centessa Pharmaceuticals, up from -$250.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$230.2 million in Q1 2024 to a low of -$544.5 million in Q1 2022.
- A 4-year average of -$357.5 million and a median of -$303.6 million in 2023 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: tumbled 87.95% in 2024, then surged 52.51% in 2025.
- Centessa Pharmaceuticals' Enterprise Value stood at -$393.6 million in 2022, then soared by 34.83% to -$256.5 million in 2023, then crashed by 87.95% to -$482.2 million in 2024, then surged by 48.94% to -$246.2 million in 2025.
- Per Business Quant, the three most recent readings for CNTA's Enterprise Value are -$246.2 million (Q3 2025), -$250.7 million (Q2 2025), and -$284.5 million (Q1 2025).